2,2-dimethyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine | 40358-36-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 2,2-dimethyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine
• 英文别名: 2,3,4,5-Tetrahydro-2,2-dimethyl-1H-1,5-benzodiazepin；2,2-dimethyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine；4,4-Dimethyl-1,2,3,5-tetrahydro-1,5-benzodiazepine
• CAS: 40358-36-9
• 化学式: C₁₁H₁₆N₂
• 分子量: 176.261
• InChiKey: WCTGDIBMEQMCDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4,4-dimethyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one 以 四氢呋喃 、 水 为溶剂， 以77.2%的产率得到2,2-dimethyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine
  参考文献：
  名称：

  2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION

  摘要：

  本发明的目的是提供一种用化学式（1）表示的2,3,4,5-四氢-1H-1,5-苯二氮䓬衍生物，或其药学上可接受的盐，作为治疗和预防糖尿病、糖尿病肾病或肾小球硬化的药剂。

  公开号：

  EP1820799A1

文献信息

• WO2006/51851
  申请人：——

  公开号：——

  公开（公告）日：——
• BROMODOMAIN INHIBITORS AND USES THEREOF
  申请人：Constellation Pharmaceuticals, Inc.

  公开号：EP2705039A2

  公开（公告）日：2014-03-12
• HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20170224713A1

  公开（公告）日：2017-08-10

  A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents —O— or —CH 2 —; R 1 represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R 2 and R 3 , which are the same or different, each independently represent hydrogen or a lower alkyl group; or R 2 and R 3 are bonded to form a cyclo-C3-C8 alkyl group; and R 4 represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).
• [EN] BROMODOMAIN INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE BROMODOMAINES ET LEURS UTILISATIONS
  申请人：CONSTELLATION PHARMACEUTICALS INC

  公开号：WO2012151512A2

  公开（公告）日：2012-11-08

  The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
• 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION
  申请人：Wakamoto Pharmaceutical Co., Ltd.

  公开号：EP1820799A1

  公开（公告）日：2007-08-22

  The present invention has its object to provide a 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented with the Formula (1) , or the pharmaceutically acceptable salt, which is effective as a therapeutic and prophylactic agent for diabetes, diabetic nephropathy, or glomerulosclerosis.

  本发明的目的是提供一种用化学式（1）表示的2,3,4,5-四氢-1H-1,5-苯二氮䓬衍生物，或其药学上可接受的盐，作为治疗和预防糖尿病、糖尿病肾病或肾小球硬化的药剂。